Valued at a market cap of nearly $120.6 billion, the company’s lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi, and Kalydeco, which are collectively approved to treat people with CF.

Vertex currently markets four cystic fibrosis (CF) products — Trikafta/Kaftrio, Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. Revenues in fourth-quarter 2023 are likely to have ...

Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...